Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Dec;50(12):2201-2206.
doi: 10.1007/s11255-018-1940-8. Epub 2018 Aug 2.

Effect of daprodustat on anemia in patients with chronic kidney disease: a meta-analysis

Dengpiao Xie  1 , Jianting Wang  2 , Xinping Wu  1 , Mingquan Li  3
Affiliations
Review

Effect of daprodustat on anemia in patients with chronic kidney disease: a meta-analysis

Dengpiao Xie et al. Int Urol Nephrol. 2018 Dec.

Abstract

Background: The efficacy of daprodustat for the treatment of anemic patients with chronic kidney disease (CKD) remains controversial. The aim of the study is to perform a meta-analysis of randomized controlled trials to evaluate the efficacy and safety of daprodustat for anemic patients with chronic kidney disease.

Methods: We searched Medline, Embase, Science Citation Index, Cochrane Central Register of Controlled Trials, and Clinical Trial Registries for randomized controlled trials comparing daprodustat with placebo for anemic patients with CKD.

Results: Four studies were included. Compared with placebo groups, daprodustat groups significantly increased hemoglobin (WMD 1.29 g/dL; 95% CI 0.96-1.62, p < 0.00001), transferrin (WMD 0.67 g/dL; 95% CI 0.45-0.89, p < 0.00001), and total iron binding capacity (WMD 9.97 g/dL; 95% CI 6.07-13.8, p < 0.00001). Daprodustat groups significantly decreased hepcidin (WMD - 76.1 μg/L; 95% CI - 91.8 to - 60.3, p < 0.00001) and ferritin (WMD - 63.6 μg/L; 95% CI - 96.6 to - 30.7, p = 0.0002) compared with that of placebo groups. In addition, there was no significant difference in adverse events between the two groups.

Conclusion: Daprodustat could improve hemoglobin without increasing adverse events in the short term. Daprodustat may be another valuable choice for anemic patients with chronic kidney disease in the future.

Keywords: Chronic kidney disease; Daprodustat; Meta-analysis.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. J Am Soc Nephrol. 2016 Apr;27(4):1234-44 - PubMed
    1. J Clin Invest. 2002 Oct;110(7):1037-44 - PubMed
    1. Kidney Int Suppl. 2007 Nov;(107):S4-9 - PubMed
    1. Am J Kidney Dis. 2010 Apr;55(4):726-41 - PubMed
    1. J Am Coll Cardiol. 2002 Jun 5;39(11):1780-6 - PubMed

MeSH terms

LinkOut - more resources